Trends in the organization of drug research: Interfacing industry and universities

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 43, Issue 3, 1997, Pages 243-252

  Meijer, D K F ^a,c   Wilting, J ^b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Academic industrial research networks; Drug innovation model; New drug research methods; Organization of drug research; Pharmacoepidemiology

Indexed keywords

CLINICAL PRACTICE; DRUG DESIGN; DRUG FORMULATION; DRUG INDUSTRY; DRUG MARKETING; DRUG MONITORING; DRUG RESEARCH; EUROPE; POLITICS; REVIEW; SOCIAL ASPECT;

EID: 0031402166     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0939-6411(97)00054-4     Document Type: Review

References (15)

1. H. Leufkens, F. Haaijer-Ruskamp, A. Bakker, G. Dukes, Scenario analysis of the future of medicines. Br. Med. J., 309 (1994) 1136-1140.
2. D.K.F. Meijer. Pharmaceutical sciences in the Netherlands: Preparations for the 21st century. Pharm. Weekbl., 127 (1992) 982-988.
3. A. Abbot, The European pharmaceutical outlook. Nature, 361 (1993) 765-768.
4. R. MacInnes, C.E. Lumley, S.R. Walker, New chemical entity output of the international pharmaceutical industry from 1970 to 1992. Clin. Pharmacol. Therap., 56 (1994) 339-349.
5. D. Blumenthal, N. Causino, E. Campbell, K.S. Louis, Relationships between academic institutions and industry in the life sciences-an industry survey. N. Engl. J. Med., 334 (1996) 368-373.
6. P.G.M. Bloemen, P.A.J. Henricks, L. van Bloots, M.C. van den Tweel, A.C. Bloem, F.P. Nijkamp, D.J.A. Crommelin, G. Storm, Adhesion molecules: A new target for immunoliposome-mediated drug delivery. FEBS Lett., 357 (1995) 140-144.
7. R.M.J. Liskamp, Opportunities for new chemical libraries: Unnatural biopolymers and diversomers. Angew. Chem. Int. Ed. Engl., 33 (1994) 633-636.
8. R.M.J. Liskamp, Conformational restricted amino acids and dipeptides, (non) peptidomimetics and secondary structure mimetics. Recl. Trav. Chim. Pays-Bas, 113 (1994) 1-9.
9. P. Olinga, M.T. Merema, D.K.F. Meijer, M.J.H. Slooff, G.M.M. Groothuis, Use of human liver slices and hepatocytes in metabolism, in: D. Crommelin, P. Couvreur, D. Duchêne, D. (Eds.), In Vitro and Ex Vivo Test Systems to Rationalize Drug Design and Delivery. Minutes European Symp., Paris, 13-14 December 1993, APGI, FIP. Paris: Editions de Santé, (1994) 204-208.
10. D.K.F. Meijer, G. Molema, Targeting of drugs to the liver, in: Seminars in Liver Disease, Vol. 15. Thieme Medical Publishers, 3 (1995) 202-256.
11. G. Molema, L.F.M.H. de Leij, D.K.F. Meijer, Tumor vascular endothelium: Barrier or target in tumor directed drug delivery and immunotherapy. Pharmaceutical Research, 14 (1997) 2-10.
12. J.H. Proost, D.K.F. Meijer, MW/PHARM, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput. Biol. Med., 22 (3) (1992) 155-163.
13. F.M. Haaijer-Ruskamp, Drug-utilization studies in the Nether-lands. Pharmaceutisch Weekblad Sci., 12 (1990) 91-96.
14. R. Vos, Drugs looking for diseases. Innovative drug research and the development of the beta blockers and the calcium antagonists, in: Developments in Cardiovascular Medicine Vol. 120, Kluwer Academic Publishers, Dordrecht, 1991.
15. R.M.C. Herings, A. de Boer, B.H.Ch. Stricker, H.G.M. Leufkens, A.J. Porsius, Hypoglycemia associated with use of inhibitors of angiotensin converting enzyme. Lancet, 345 (1995) 1195-1198.